The present invention is directed to benzamide compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
-
Page/Page column 80
(2015/11/09)
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced p K a: Antibacterial agents with an improved safety profile
Novel non-fluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance with fluoroquinolones. N-L
Reck, Folkert,Alm, Richard A.,Brassil, Patrick,Newman, Joseph V.,Ciaccio, Paul,McNulty, John,Barthlow, Herbert,Goteti, Kosalaram,Breen, John,Comita-Prevoir, Janelle,Cronin, Mark,Ehmann, David E.,Geng, Bolin,Godfrey, Andrew Aydon,Fisher, Stewart L.
p. 6916 - 6933
(2012/10/07)
More Articles about upstream products of 1034057-93-6